Initiation of Guideline-Matched Oral Anticoagulant in Atrial Fibrillation-Related Stroke
Mi‐Yeon Eun, Jae Young Kim, Yang‐Ha Hwang, Man‐Seok Park, Joon‐Tae Kim, Kang‐Ho Choi, Jin‐Man Jung, Sungwook Yu, Chi Kyung Kim, Kyungmi Oh, Tae-Jin Song, Yong‐Jae Kim, Beom Joon Kim, Sung Hyuk Heo, Kwang‐Yeol Park, Jeong‐Min Kim, Jong‐Ho Park, Jay Chol Choi, Jong‐Won Chung, Oh Young Bang, Gyeong‐Moon Kim, Woo‐Keun Seo
Abstract
BACKGROUND AND PURPOSE: To evaluate the outcome events and bleeding complications of the European Society of Cardiology (ESC) guideline-matched oral anticoagulant therapy for patients with acute ischemic stroke and atrial fibrillation (AF). METHODS: Patients with acute ischemic stroke and AF from a nationwide multicenter registry (Korean ATrial fibrillaTion EvaluatioN regisTry in Ischemic strOke patieNts [K-ATTENTION]) between January 2013 and December 2015 were included in the study. Patients were divided into the ESC guideline-matched and the non-matched groups. The primary outcome was recurrence of any stroke during the 90-day follow-up period. Secondary outcomes were major adverse cerebrovascular and cardiovascular events, ischemic stroke, intracranial hemorrhage, acute coronary syndrome, allcause mortality, and major hemorrhage. Propensity score matching and logistic regression analyses were performed to assess the effect of the treatments administered. RESULTS: Among 2,321 eligible patients, 1,126 patients were 1:1 matched to the ESC guidelinematched and the non-matched groups. As compared with the non-matched group, the ESC guideline-matched group had a lower risk of any recurrent stroke (1.4% vs. 3.4%; odds ratio [OR], 0.41; 95% confidence interval [CI], 0.18 to 0.95). The risk of recurrent ischemic stroke was lower in the ESC guideline-matched group than in the non-matched group (0.9% vs. 2.7%; OR, 0.32; 95% CI, 0.11 to 0.88). There was no significant difference in the other secondary outcomes between the two groups. CONCLUSIONS: ESC guideline-matched oral anticoagulant therapy was associated with reduced risks of any stroke and ischemic stroke as compared with the non-matched therapy.